Drug Discovery for Parasitic Diseases

 说明(由申请人提供)：请为Leann M.Tilley、Philip J.Rosenthal和Kelly Chibale组织的题为寄生虫病药物发现的Keystone研讨会提供支持。会议将于2016年1月24-28日在加利福尼亚州塔霍市举行。包括原生动物和蠕虫在内的寄生生物是人类最重要的病原体之一，每年导致数十亿人感染和数百万人死亡。对于许多寄生虫病，现有的治疗方法并不令人满意，而且越来越多地受到耐药性的威胁。迫切需要新的治疗方法，最好是针对新的靶点。最近在抗寄生虫药物发现方面的进展来自三种不同的方法--建立在对寄生虫生物学更好理解的基础上的靶向方法；受益于改进的技术的表型高通量筛选；以及为其他适应症开发的药物的重新定位和重新用途。这些不同的方法都受益于药物化学与寄生虫学和药物治疗计划的整合。这次会议将展示尖端的抗寄生虫药物发现项目，这些项目展示了从寄生虫生物学到领先鉴定以及从优化到候选选择的路径。它将强调在药物化学、寄生虫生物学、药代动力学和安全性评估方面协调整合计划的必要性。它将展示促进药物发现的新兴技术，如化学生物学、化学蛋白质组学、化学信息学、基因组学、转录组学和代谢组学。还将讨论抗寄生虫耐药的现状和我们对耐药机制的理解进展。药物化学家、寄生虫学家、药物发现和开发专家、药理学家和临床医生应该对导致严重人类疾病的原虫和蠕虫感兴趣，这些原虫和蠕虫包括疟疾、非洲和美洲锥虫病、利什曼病、血吸虫病和多种其他寄生虫病。

 DESCRIPTION (provided by the applicant): Support is requested for a Keystone Symposia meeting entitled Drug Discovery for Parasitic Diseases, organized by Leann M. Tilley, Philip J. Rosenthal and Kelly Chibale. The meeting will be held in Tahoe City, California from January 24-28, 2016. Parasitic organisms, including protozoa and helminths, are among the most significant human pathogens, causing billions of infections and millions of deaths each year. For many parasitic diseases, available therapies are unsatisfactory and increasingly threatened by drug resistance. New therapies, ideally directed against novel targets, are urgently needed. Recent advances in anti-parasitic drug discovery have come from three different approaches - target-based methods that build on improved understanding of parasite biology; phenotypic high throughput screens, that are benefitting from improved technology; and repositioning and repurposing drugs developed for other indications. These different approaches all benefit from the integration of medicinal chemistry with parasitology and pharmacotherapy programs. This conference will showcase cutting-edge anti-parasitic drug discovery programs that illustrate the path from parasite biology to lead identification and from optimization to candidate selection. It will emphasize the need for coordinated integration of programs in medicinal chemistry, parasite biology, pharmacokinetics, and safety assessment. It will feature emerging technologies such as chemical biology, chemoproteomics, chemical informatics, genomics, transcriptomics and metabolomics that are facilitating drug discovery. It will also discuss the current status of anti-parasitic drug resistance and advances in our understanding of mechanisms of resistance. The conference should be of interest to medicinal chemists, parasitologists, experts in drug discovery and development, pharmacologists and clinicians targeting the protozoa and helminths that cause serious human disease, including malaria, African and American trypanosomiasis, leishmaniasis, schistosomiasis and multiple other parasitic infections.